Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serine-glycine biosynthetic pathway diverts the glycolytic intermediate 3-phosphoglycerate to synthesize serine and glycine, of which the latter was found to correlate with cancer cell proliferation. Increased de novo biosynthesis of glycine by
serine hydroxymethyltransferase 2
(
SHMT2
) is the central mechanism to fuel one-carbon pools supporting tumorigenesis. However, the therapeutic potential in targeting
SHMT2
in hepatocellular carcinoma (HCC) is unknown. In this study we showed that
SHMT2
inhibition significantly suppressed liver tumorigenesis. In vitro,
SHMT2
-knockdown was found to reduce cell growth and tumorigenicity in Huh-7 and HepG2
liver cancer
cells. Moreover
SHMT2
-knockdown Huh-7 cells failed to form tumor xenograft after subcutaneous inoculation into nude mice. Similarly, inducible
SHMT2
inhibition, via doxycycline-added drinking water, was found to reduce tumor incidence and tumor growth in a human tumor xenograft mouse model.
SHMT2
-knockdown increased the susceptibility of Huh-7 cells to doxorubicin suggesting its potential in combination chemotherapy. Through isotopomer tracing of [2-13C] glycine metabolism, we demonstrated that
SHMT2
activity is associated with cancer phenotype. However, overexpression of
SHMT2
was insufficient to transform immortalized hepatic cells to malignancy, suggesting that
SHMT2
is one of the building blocks in
liver cancer
metabolism but does not initiate malignant transformation. Moreover, our results suggest that glycine, but not 5,10-methylenetetrahydrofolate, from the
SHMT2
-mediated enzymatic reaction is instrumental in tumorigenesis. Indeed, we found that
SHMT2
-knockdown cells exhibited increased glycine uptake. Taken together, our data suggest that
SHMT2
may be a potential target in the treatment of human HCC.
...
PMID:Downregulating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma. 2739 39